A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show ...

By reducing inflammation, the researchers were able to prevent both the buildup of immune cells and the formation of these ...

The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...

University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect against age-related macular degeneration (AMD)-like pathology in preclinical ...

Panelists discuss how differing disease mechanisms, inflammatory drivers, and clinical priorities across AMD, DME, and RVO ...

The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals ...

Editing a gene known to increase risk of Alzheimer’s with a gene associated with lower risk shows promise for treating the ...

ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA ...

Menlo Park resident Carmen Caricchio is on a quest to cure childhood inherited retinal diseases, a group of rare conditions that cause the degeneration of the retina and can lead to vision impairment ...

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...

The gene therapy will utilize the firm's suprachoroidal vector coAAV-SCS, which it says will be an effective and less burdensome treatment alternative.

In a first-in-human phase 1/2a clinical trial, researchers used adult stem cells to help restore vision in people with age-related macular degeneration. In the United States, age-related macular degen ...